- Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90% PSA reduction (PSA90)
- Nine of 35 patients (25.7%) with measurable mCRPC achieved confirmed partial responses
- Manageable overall safety profile observed across multiple expansion cohorts
- Company plans to initiate Phase 2 study in mCRPC in 2023M
Tronox Holdings Q3 EPS $0.69 Misses $0.77 Estimate, Sales $895.00M Beat $894.70M Estimate
Tronox Holdings (NYSE:TROX) reported quarterly earnings of $0.69 per share which missed the analyst consensus estimate of $0.77 by 10.39 percent. This is a 4.17 percent decrease over earnings of $0.72 per share from the
